Latest News

  • Kodiak Sciences Inc. Announces Pricing of Initial Public Offering

    Palo Alto, CA, October 3, 2018 – Kodiak Sciences Inc. (“Kodiak”) today announced the pricing of its initial public offering …

    Read Article
  • Kodiak Sciences Inc. Announces Launch of Initial Public Offering

    Palo Alto, CA, September 24, 2018 – Kodiak Sciences Inc. (“Kodiak”) today announced that it has launched an initial public …

    Read Article
  • Kodiak Sciences Expands Leadership with Industry Veterans Including Appointment of Jason Ehrlich, M.D., Ph.D., as Chief Medical Officer and Chief Development Officer

    Palo Alto, CA, September 17, 2018 – Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to …

    Read Article

Our Science: Pushing the Boundaries

At Kodiak, we are developing disruptive product platforms designed to prevent and treat the leading causes of blindness

ABC PlatformTM

CLiP PlatformTM

Our Pipeline

We are committed to progressing and expanding our pipeline towards the prevention, treatment and, when possible, the cure of high-prevalence ophthalmology diseases.

Working at Kodiak

We aspire to global leadership in ophthalmology through internal development and by aggregating top talent, technologies, discoveries and ideas